Symprove has been subject of six independent clinical trials.
An independent study carried out at King’s College London by Dr Guy Sisson and Professor Ingvar Bjarnason looked at the effects of Symprove on pain, constipation and diarrhoea on IBS sufferers with moderate to severe symptoms. The study concluded that significant improvements was seen in 4 weeks and continued through the full 12 weeks of the study. The results were published in the AP&T in 2014.
An independent study carried out by Darent Valley Hospital and King’s College London looked to establish the effect of Symprove in IBD patients with ulcerative colitis. It found that 76% of patients with ulcerative colitis had significant reductions in faecal levels of calprotectin - a protein released by cells in the intestine when it is inflamed - following a course of Symprove. The results were published in Gastroenterology journal in 2015.
An independent study carried out at King’s College Hospital London by Dr Savvas Papagrigoriadis and Professor Ingvar Bjarnason to establish the efficacy of Symprove in diverticular disease. The study concluded that Symprove had a significant benefit on reducing the frequency of constipation, diarrhoea, mucorrhea and back pain. Symprove also prevented an escalation in inflammatory activity in males and was associated with fewer diverticulitis episodes in a subgroup of patients. The results of the study were presented at the leading world Gastroenterology congress, Digestive Disease Week, San Diego, in May 2016.
A further independent study was carried out by Dr Simon Gaisford of University College London School of Pharmacy. He studied eight well-known market-leading probiotics to establish if they safely arrive survive stomach acids and thrive in the target area of the gut. Symprove was the only one to meet all three challenges. The results were published in Beneficial Microbes journal in 2015.
Symprove has been shown to inhibit the growth of pathogenic bacteria and promote a healthier gut environment by three independent studies. The studies found Symprove inhibits the growth of C. difficile, Esherichia coli (E.Coli) - AIEC phenotype, Shigella sonnei and MRSA.
Welcome to Symprove Holdings Limited scientific website.
To access this site, please confirm that you are a healthcare professional, scientist or journalist.